Onco Actu du 24 avril 2017

	2.4 Etiologie - Portables, ondes e-m
Brain Tumour Charity cautious about Italy mobile phone ruling [BBC News] "However, the global research projects that have been conducted so far, involving hundreds of thousands of people, have found insufficient evidence that using a mobile phone increases the risk of developing a brain tumour."
	2.7 Etiologie - Obésité
Obesity behind surge in kidney cancers [Cancer Research UK] “Similar to smoking, where damage to cells builds up over time and increases the risk of cancer, damage from carrying excess weight accumulates over a person’s lifetime."
Obesity blamed for sharp rise in kidney cancer in UK [The Guardian] The charity’s projections show kidney cancer cases climbing by a further 26% by 2035, which would make it one of the fastest growing types of cancer.
	3.6 Prévention - Activité physique
Cycling commuters have lower rates of heart disease and cancer [NHS Choices] Although this is an observational study, confidence in the link is improved by its consistency with existing knowledge and research on the benefits of physical activity and the graded response in the results.
	4.12 Biopsies liquides
GRAIL Initiates the STRIVE Study to Advance Development of Blood Tests to Detect Cancer Early [Grail] STRIVE is a longitudinal, prospective, observational study that will enroll up to 120,000 women at the time of their screening mammogram to train and validate a blood test to detect breast cancer. Additionally, the study will be used to develop a pan-cancer test to detect multiple cancers at early stages.
	5. Traitements
New technique tests therapies for breast cancer metastasis [Baylor College of Medicine] To mimic the interactions between metastatic breast cancer cells and bone cells in a living system in the lab, Zhang and his colleagues developed a bone metastasis model, called bone-in culture array, by fragmenting mouse bones that already contain breast cancer cells.
More surgeons must start doing basic science [Nature] They say they don't have the time or incentives to do research — and that’s dangerous for translational medicine.
	5.12 Immunothérapies
CRISPR genome editing and immunotherapy – the early adopter [Cancer Research UK] Some of the research that’s taken place since CRISPR burst onto the scene has also raised more questions than answers. The immune system is a powerful and complicated machine, and we don’t yet understand how to control it.
Immunotherapy Pioneer James Allison Has Unfinished Business with Cancer [MIT Technology Review] By now, Allison is almost used to adulation. There are even murmurings that his work in cancer immunotherapy might win him the Nobel Prize. Twenty years ago, he was the first to show it’s possible to turbocharge the body’s response to cancer with a drug that releases the immune system so that it destroys tumors on its own.
	5.2 Pharma
XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection [The Street] XBiotech's efforts to shade Xilonix's clinical failings amounted to little more than hand waving when it mattered most. European regulators at the oral explanation meeting on Thursday were not fooled.
XBiotech shares crater as CHMP shudders at its application to sell Xilonix [EndPoints] The EMA’s Committee for Medicinal Products for Human Use — the CHMP — put together an informal trend vote on the biotech’s application for Xilonix as a new drug for colorectal cancer, providing a hard signal the formal vote will go against XBiotech after concluding the biotech has no data to prove that the drug works.
	5.3 Traitements - FDA, EMA, NICE...
EU drugmakers urge June decision on new location for watchdog [Reuters] "Were a rapid resolution on the future location of the EMA not to materialize, or if the future seat of the European Medicines Agency were to fail in terms of establishing its minimum prerequisites, the quality of its work and the future of the European Medicines Regulatory Network would be placed in jeopardy."
	5.3.4 Traitements - AMM (FDA, EMA)
Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia [Pfizer] The Marketing Authorization Application (MAA) for BESPONSA was based on results from the Phase 3 INO-VATE 1022 trial, which enrolled 326 adult patients with relapsed or refractory B-cell ALL, and compared BESPONSA to standard of care chemotherapy.
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer [BMS] CHMP opinion based on tumor response rate and duration of response demonstrated in Phase 2 CheckMate -275 trial.
Pending EC decision: Avastin, bevacizumab, Opinion date: 21-Apr-2017 [EMA] The CHMP adopted an extension to an existing indication as follows: "Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents".
Pending EC decision: Opdivo, nivolumab, Opinion date: 21-Apr-2017 [EMA] The CHMP adopted a new indication as follows: 'Opdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.'
	5.4 Traitements - Economie
England “really is not a good place” to get cancer, BMS UK General Manager says [Pharmafile] Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to life-saving treatments on the NHS, claiming the UK is falling behind its neighbours in Europe.
	5.6 ESMO
ELCC 2017 Media Alert: European Lung Cancer Conference Preview [ESMO] The European Lung Cancer Conference is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
	6. Lutte contre les cancers
Making Greater Progress Against Cancer—Not Just a Hope but a Reality [NCI] The optimistic portrait of our progress against cancer led me to also reflect upon other ways we can know whether we are making progress.
	6.12 Ethique
What Henrietta Lacks’s story taught me about trust and my role as a doctor [STAT] This doctor got it — a history of not just racial discrimination, but human rights violations. And that was an answer I could trust.
Should You Worry About Being the Next Henrietta Lacks? [NY Times] Researchers have produced over 20 tons of those cells — called “HeLa cells” after her name — facilitating the development of new drugs and vaccines, aiding many millions of patients and earning biotech and pharmaceutical companies hundreds of millions of dollars in profits.